JJP Biologicssp. z o.o.

Research and experimental development in natural sciences and engineering

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2016-03-23
Share capital
3 198 900,00 PLN
Activity description

JJP Biologics is a Polish biotechnology company developing biological therapeutics supported by established companion diagnostics and a personalized-medicine strategy. Its pipeline includes JJP-1212, a potential CD89 antagonist for autoinflammatory diseases, and JJP-1008, a potential HVEM checkpoint inhibitor for solid tumors; the company seeks academic collaborators, investors, and biotechnology partners.

Registered address
ul. Bobrowiecka 6, 00-728 Warszawa, Poland
Website
jjpbiologics.comWebsite active
Phone
Social media
Electronic delivery address
AE:PL-80487-77162-HTUID-28

Financials

Revenue history (in k)

Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2025.

Results vs industry

Revenue
This companyUSD 5.00mMedianUSD 133.91kAverageUSD 4.65m
Net profit
This companyUSD -13.58mMedianUSD -54.78AverageUSD 310.10k
Operating costs
This companyUSD 17.71mMedianUSD 175.72kAverageUSD 4.46m
Assets
This companyUSD 17.76mMedianUSD 254.44kAverageUSD 8.12m

Bank accounts

Registered as a VAT taxpayer on 2016-05-25. Active

Debt

No entries in the National Debtors Register (KRZ). No proceedings in KRZ

Real estate

TypeAmount
Buildings and premises
PLN 50,375

MSiG notices

Publication dateEvent
Feb 5, 2024Call to creditors
Nov 18, 2020Call to creditors

Public aid

13 public aid cases recorded, with a total value of $22,776,051.

PurposeGross amount
Aid for research and development projects: experimental development
$4.4M
Aid for research and development projects: industrial research
$4.2M
De minimis aid (in accordance with Commission Regulation 2023/2831)
$18,834

European Funds

ProjectEU co-financing
Opracowanie innowacyjnej cząsteczki, przeznaczonej do immunoterapii gruczolakoraka płuc, indukującej mechanizm ukierunkowanej degradacji lizosomalnej
$8.4M

Tenders

No recorded participation in tenders.

Authorized Representatives

Paweł Aleksander Szczepański – President of the Management Board
Louis Boon – Management Board Member
Dariusz Krzysztof Piątek – Management Board Member
Grzegorz Roman Kotowski – Management Board Member

Manner of representation

The making of declarations on behalf of the company requires the joint action of two members of the management board, or of one member of the management board jointly with a commercial proxy.

Supervisory board

Abraham Bout – Supervisory Board Member
Marek Krzysztof Cybulski – Supervisory Board Member
Joerg Windisch – Supervisory Board Member
Konstantin Matentzoglu – Supervisory Board Member

Ownership

OwnerSharesShare valueStake
57,580$777,687.7489.9997%
Jerzy Andrzej Starak
6,398$86,169.649.9722%
Others
18$243.110.0281%

Beneficial owners

Person

Subsidiaries

NameStake
Jjpb1008sp. z o.o.
99%
Jjpb1212sp. z o.o.
99%
Jjpbonkosp. z o.o.
99%

Competitors

Change history

DateEvent
2025-12-05Share capital change
2025-05-19PKD change
2024-07-03Share capital change
2022-12-01Address change
2022-05-01Share capital change

FAQ

Last updated: 2026-07-20